Celtec Inc.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
Dendritic Cell Cancer Therapy
The content above was translated by Ai
Founded Year
2016
Unified Business No.
52464901
Status
Active
Number of Employees
0
Total Paid-in
Capital
22,800,000 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
The founder of Zentai Biotech previously worked at Fountain Biopharma and SynCore Biotechnology under the Microbio Group, and once conducted drug development under the late Harvard University professor Dr. Judah Folkman, the internationally renowned "Father of Angiogenesis," participating in the development of three angiogenesis inhibitor drugs with total annual sales exceeding USD 15 billion. Zentai Biotech specializes in the fields of immunotherapy and immune cell therapy, and has already achieved significant results in the application and development of dendritic cells.
The content above was translated by Ai
